Procter & Gamble Downgraded to Hold at $156 While UBS Cuts Target to $161
Procter & Gamble shares are down 6% over the past year but up 13% year-to-date, with organic sales growth stalling at 0% last year. TD Cowen downgraded the stock to Hold with a $156 target, UBS cut its Buy target to $161 and Berenberg keeps a Hold rating at $156.
1. Recent Share Performance and Growth Stagnation
Procter & Gamble shares have declined 6% over the last year but climbed 13% year-to-date, while the company’s organic sales growth remained at 0% over the past 12 months. This stagnation has heightened focus on top-line recovery ahead of upcoming fiscal quarters.
2. Analyst Rating and Price Target Changes
TD Cowen moved Procter & Gamble to a Hold rating with a $156 price target, UBS reduced its Buy target to $161 from $176, and Berenberg continues to rate the stock Hold at $156. These adjustments reflect cautious sentiment as management works to reinvigorate growth.
3. Market Sentiment and Growth Expectations
Commentators have hailed Procter & Gamble as a reliable “machine” for cash generation despite weak organic growth, underscoring confidence in its durable margin profile. Investors are watching for signals of accelerating sales momentum as cost pressures ease.